CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale 10% owner sold 219,853 shares at an average $44.04 ($9,682,651)
- 4 Open-market sale 10% owner sold 314,792 shares at an average $42.50 ($13,379,623)
- 4 Open-market sale 10% owner sold 390,984 shares at an average $42.18 ($16,491,046)
- 4 Grant or award Director acquired 9,969 shares (grant or award)
- 4 Grant or award Director acquired 9,969 shares (grant or award)
- 4 Grant or award Director acquired 9,969 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 489,220 shares at an average $47.40 ($23,188,152)
- 4 Open-market buy Director bought 146,382 shares at $47.00 ($6,879,954)
- 4 Other acquisition Director acquired 8,039 shares (other)
- 4 Gift President and CEO gave 856,044 shares (gift)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Technical Officer acquired 30,800 shares (grant or award)
- 4 Grant or award EVP of R&D and CMO acquired 30,800 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 30,800 shares (grant or award)
- 4 Open-market sale Chief Technical Officer sold 3,750 shares at $19.19 ($71,980)
- 4 Open-market sale Chief Financial Officer sold 5,450 shares at an average $19.73 ($107,508)
- 4 Open-market sale President and CEO sold 20,335 shares at an average $19.31 ($392,615)
Page 11 of 14 · 275 filings